clinical outcomes, but the association between induction immunosuppressant type and pathologic findings remains still uncertain.Methods: We investigated the association between induction immunosuppressive agents and one-year protocol biopsy findings in KTRs with stable allograft function between 2017 and 2023.Post-transplant outcomes and histopathological patterns in one-year protocol biopsies were compared between KTRs who received basiliximab and thymoglobulin.Results: A one-year protocol biopsy was performed in 88 KTRs (48 from living and 40 from deceased donors).Among them, 45 (51.1%) showed nonspecific changes, 5 (5.7%), borderline, 18 (20.3%),subclinical rejection: 4 (4.5%),acute T-cell mediated rejection (TCMR), 3 (3.4%),chronic active TCMR, 10 (11.4%), acute antibody-mediated rejection (ABMR), 1 (1.1%), chronic active ABMR, 4 (4.5%), de novo glomerulopathy/recurrence of primary disease, 4 (4.5%)calcineurin inhibitor toxicity, 11 (12.5%),interstitial fibrosis and tubular atrophy, and 1 (1.1%),BK virus nephropathy.There was no significant difference of baseline characteristics between basiliximab and thymoglobulin groups.The number of global sclerosis, cg score, ci score, t-IFTA, ct score, cv score, ah score, and aah score was significantly higher in basiliximab group than thymoglobulin group.However, there were no significant differences of the occurrence of de novo donor specific antibody (DSA) and subclinical rejection between them.Conclusion: Although kidney function is stable within one-year after transplant, protocol biopsies accounts for potential pathological changes.This study showed that induction immunosuppressant type was not significantly associated with the development of de novo DSA and subclinical rejection, but use of basiliximab was associated with more pronounced chronic allograft injury than thymoglobulin.I have no potential conflict of interest to disclose.I did not use generative AI and AI-assisted technologies in the writing process.
Park et al. (Wed,) studied this question.